Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06536179
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-26
Brief Title:
New Preclinical and Clinical Approaches to Mesothelioma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
New Preclinical and Clinical Approaches to Mesothelioma an Archetypal Inflammatory Tumor
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study protocol involves the coordination between UO1 IRCCS San Raffaele Hospital and UO2 Istituto Nazionale Tumori di Napoli - IRCCS G Pascale to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis UO1 focuses on the role of HMGB1 in inflammation mesothelioma progression and tissue repair as well as developing in future possible HMGB1 inhibitors for cancer therapy UO2 specializes in CXCR4s role in cancer developing CXCR4 antagonists and tracking CXCR4-dependent metastasis The hypothesis is that targeting HMGB1 and CXCR4 pathways will inhibit tumor progression and metastasis enhancing anti-tumor immunity and improving therapeutic outcomes in cancer
Detailed Description:
This is a multicentric cross-sectional observational study with an additional blood volume collected during blood sampling performed for normal clinical practice The enrollment will take
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None